Navigation Links
Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/6/2008

sitively impacted our net results.

At December 31, 2007, cash and cash equivalents were $20.9 million and restricted cash was $958 thousand. In the fourth quarter of 2007, cash provided by operations was $1.9 million and cash used for capital expenditures was $61 thousand. In the fourth quarter of 2007, Orchid Cellmark completed the acquisition of ReliaGene, a provider of forensic and paternity DNA testing services based in New Orleans, Louisiana. The net aggregate purchase price was $5.4 million in cash and 560,539 shares of Orchid Cellmark common stock (valued at $2.9 million). As a result of the ReliaGene acquisition, Orchid Cellmark assumed $240 thousand of short-term and $525 thousand of long-term debt, of which $188 thousand is current, as of December 31, 2007.

Orchid Cellmark recently was awarded a significant portion of the work that it bid for in the North West/South West and Wales regional tender (internally referred to as the mega tender) primarily for DNA related work. The award followed a lengthy competitive bidding process. Under the award, Orchid Cellmark will provide forensic services for several police forces from this region and will carry out DNA testing of database crime scene samples, forensic casework and PACE samples (DNA database under the Police and Criminal Evidence Act). It is anticipated that work from this award will commence in the second quarter of 2008 after the completion of contracts with each of the police forces. Also in the U.K., as previously reported, Orchid Cellmark performs forensic testing services for several police forces in the U.K. through an arrangement with LGC, the successor to Forensic Alliance Ltd. The agreement with LGC was terminated effective July 15, 2007, and although Orchid Cellmark has been continuing to provide its services through subcontract extension agreements, LGC will likely seek to provide DNA services directly to two key police forces in the U.K. that are presently serviced by Orchid Ce
'/>"/>

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
2. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
3. Orchid Cellmark Reports Third Quarter 2007 Financial Results
4. MDS Reports First Quarter 2008 Results
5. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2007 Financial Results
6. Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008
7. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
8. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
11. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... 10, 2014) Obese and overweight firefighters are ... care providers, according to new research from The ... (UTHealth). , National guidelines state that health care ... of maintaining a healthy weight. Firefighters have high ... leading cause of line-of-duty deaths in firefighters. This ...
(Date:7/11/2014)... to repair damage to the anterior cruciate ligament (ACL) -- ... could increase a young athlete,s risk for further injuries, researchers ... aged 8 to 16, who had ACL reconstruction surgery. Of ... their injury, 37 had surgery six to 12 weeks after, ... their injury. The youngsters who had surgery later had ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3
... June 5 The combination of two different chemotherapies ... cancers is not effective against advanced melanoma, according to ... 46th annual meeting of the American Society of Clinical ... we learn something important about the treatment of melanoma," ...
... ... that a less-invasive technique called sentinel node resection is just as safe ... the underarm area, according to a new study being presented today at ... National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital ...
... chemotherapy, new drug prolonged lives of some with advanced ... report they prolonged survival for some patients with advanced ... is currently only about six months. , One ... tumors in the majority of lung cancer patients with ...
... drugs approved for treatment of drug-resistant chronic myeloid leukemia ... therapy than the existing front-line medication, according to two ... of Medicine . Separate international phase III ... treatment between the standard-of-care drug imatinib, also known as ...
... CHICAGO - Dasatanib, a medication currently approved as treatment ... quicker, better responses as a first therapy than the ... of Texas MD Anderson Cancer Center. The findings ... American Society of Clinical Oncology today, and published in ...
... early because of supplement,s poor performance , SATURDAY, June ... selenium doesn,t reduce the likelihood of lung cancer recurrence, ... D. Karp, a professor in the department of thoracic/head ... M.D. Anderson Cancer Center, is scheduled to present the ...
Cached Medicine News:Health News:Combination treatment regimen not effective against advanced melanoma 2Health News:Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors 2Health News:Researchers Report Treatment Headway Against Lung Cancer 2Health News:Researchers Report Treatment Headway Against Lung Cancer 3Health News:Second-line CML drugs evoke faster, better front-line remissions 2Health News:Second-line CML drugs evoke faster, better front-line remissions 3Health News:Second-line CML drug evokes faster response, fewer side effects, pivotal study finds 2Health News:Don't Count on Selenium to Prevent Lung Cancer Recurrence 2
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... 20 Radius Health ("Radius") announced today that it ... institutional financing round, increasing total Series C investment to ... company,s inception to $106.5 million. All existing institutional investors ... NVS Strategic Fund and including MPM Capital, The Wellcome ...
... Amgen,(Nasdaq: AMGN ) and Millennium: ... Company Limited (TSE: 4052), today announced that,enrollment in ... 706) in,combination with paclitaxel and carboplatin for the ... has been temporarily suspended,following a planned safety data ...
Cached Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7
... HYDROLYSER Percutaneous Thrombectomy Catheter is ... for rapid, effective and easy removal ... shunts. The HYDROLYSER catheter provides an ... thrombolytic therapy. ,Compatible with ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
... The AVX catheter is designed ... to 12mm. High-pressure saline jets travel ... sound to create a low pressure ... is drawn into the catheter where ...
Redel Connector 10 Pin...
Medicine Products: